Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.
Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the long-term benefits of lenalidomide (Revlimid) plus rituximab (Rituxan; R2) in mantle cell lymphoma (MCL).
During the 2020 ASH Annual Meeting and Exposition, results of a 7-year analysis from a multicenter, phase 2 trial (NCT01472562) were presented, demonstrating high rates of complete responses and durable remissions with R2 as initial treatment in younger and elderly patients with MCL.
R2 is the first chemotherapy-free regimen to be evaluated in MCL as induction treatment, says Ruan. Moreover, patients on the study continued on lenalidomide maintenance therapy following 12 cycles of therapy with R2. Notably, these long-term findings confirm that a chemotherapy-free approach is feasible and favored compared with chemotherapy-based regimens in this patient population, concludes Ruan.